Cancer oncology
Conditions
Interventions
The multidisciplinary intervention is based on and fits in seamlessly with the
recent authorized *Guideline cancer and work* (Richtlijn Kanker en Werk ) from
the Dutch union of occupational physicia
Sponsors
TNO
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - be of the working age (18-65 years). - be diagnosed with a form of cancer matching the CAS codes described below. - have a permanent contract with an employer, or a temporary contract with an employer which will end at least six months after start of the study. - good command of the Dutch language, orally and in writing.;CAS codes A209: Other Neoplasm (non-specified) B200: Hodgkin lymphoma B201: Leukemia B209: Malignancies of the hematopoetic and lymphoid tissues E209: Endocrine gland neoplasm L200: Bone metastases L209: Bone neoplasm L219: Neoplasm in muscle- and connective tissues N209: Meninges neoplasm (brain tissue) N210: Central nervous system malignancies N219: Central nervous system neoplasms (e.g. benign tumours) N229: Neoplasms in the autonomous and peripheral nervous system R200: Malignancies in the lungs or in bronchial tissue R209: Other neoplasms in the respiratory tract (non-specified) S200: Malignancies in the gasrto-intestinal tract S201: Liver metastasis S209: Other neoplasms in the gastro-intestinal tract (non-specified) U200: Kidney, bladder and urinary malignancies U219: Neoplasms in the male reproductive system U229: Neoplasms in the mammae
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Pregnancy. - Severe comorbidities of physical or psychological nature that make participation from a medical perspective irresponsible (to judgement of the company doctor). - matching one of the CAS codes described below. - Already being signed up for a reintegration track at Re-turn or another intervention aimed at return to work at work (with an exception of recovery tracks being instated from the regular healthcare). - Retirement within 24 months after reporting sick. - The employee was already reported sick prior to an insurance agreement between the employer and the Amersfoorste Verzekeringen. ;CAS codes A200: Kaposi sarcoma C209: Non-specified neoplasms in the cardiovascular system D200: Malignant melanoma D201: Other malignancies in the skin and adnex (non-specified) D209: Other neoplasms of the skin and adnex (non-specified) H209: Ear and mastoïd neoplasms U209: Other neoplasms in the kidney, bladder and urinary tract (non-specified)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The most important outcome measures of the effect study are time to return to work and quality of life. Return to work will be logged in the systems of ArboNed. In the systems of ArboNed, the registration of sickness and recovery is a dichotomous outcome measure: an employee is (partially) absent, or is completely returned to work. When an employee changes his contract during the period of absence (for example working fewer hours), this will be registered in the system. Health related quality of life will be measured using the EuroQol 5D scale, developed by the EuroQol group (EQ-5D). The EQ-5D consists of 5 scales; Mobility, Self-care, Usual activity, Pain/Discomfort and Anxiety/Depression and a 100-point visual analogue scale. The five items cover mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with three levels per item (i.e., no problem, some problems, and extreme problems). The EQ-5D is a generic instrument and has been used in cancer research in circa 200 studies. | — |
Secondary
| Measure | Time frame |
|---|---|
| Besides these outcome measures, some secondary outcomes will be taken into consideration. Among these are outcomes concerning the most common complaints among employees with cancer like fatigue and memory problems. We will also take some predictive factors into consideration. For this validated questionnaires that are found appropriate for this target group and are mentioned in the guideline Cancer and work, will be used. The concepts we will be measuring are: - Fatigue will be assessed using the Multidimensionele Vermoeidheids Index (MVI). This 20-item questionnaire is recommended in the Guideline Cancer and Work (Richtlijn Kanker en Werk). - Expectations and experiences regarding return to work will be assessed using the Return-to-work self-efficacy questionnaire (RTWSE-10). - Cognitive problems will be assessed using the Cognitieve symptomen checklist * work (CSC-W DV). This 21-item questionnaire is recommended in the guideline Cancer and Work Richtlijn Kanker en Werk. - Psychological problems using the Four Dimensional Symptom Questionnaire (4DSQ). - Data regarding healthcare costs and additional expenses will be gathered using the TIC-P questionnaire44. This questionnaire is frequently used in experimental studies to calculate the benefits of interventions and compare them to the cost of the intervention (cost-effectiveness analysis). - Work ability will be measured using one item from the Work Ability Index . All data about the obtaining of work and return to work will be collected through files from ArboNed at the end of the research period. All other data will be collected by questionnaires (self-reporting by the participant). This data is digitally available through the questionnaire system of ArboNed. For participants who are unable to complete digital questionnaires, the questionnaire will be offered through telephone interviews. Data from EuroQol and the TIC-P questionnaires can be used to perform a cost-effectiveness analysis | — |
Countries
Netherlands
Outcome results
None listed